Bharat Biotech on Tuesday announced recruitment of 13,000 volunteers and continued progress towards achieving the goal of 26,000 participants for the phase III clinical trial clinical trials of its COVID-19 vaccine ‘Covaxin’ across multiple sites in India.
Covaxin has been evaluated in approximately 1,000 subjects in phase I clinical trial and phase II clinical trial clinical trials, with promising safety and immunogenicity results, Bharat Biotech said during a statement.
The indigenously developed COVID-19 vaccine has been developed together with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV), it added.
